Azacitidine
Polycythemia Vera
M.D. Anderson Cancer CenterSmall moleculePhase 1/2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 95/ 100
Competitive context
18 Active assets in the Polycythemia Vera cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ruxolitinib University of Washington | Phase 4 | BB |
TACROLIMUS Thomas Jefferson University | Phase 2 | BB |
Pegylated-Proline-Interferon Alpha-2B AOP Orphan Pharmaceuticals AG | Phase 3 | BB |
Fludarabine Thomas Jefferson University | Phase 2 | BB |
Cyclophosphamide Thomas Jefferson University | Phase 2 | BB |
View all 36 →
Same molecule, other indications
Azacitidine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →